What is Peptyde Bio?
Peptyde Bio is an Agtech startup poised to become a leading provider of novel antimicrobial peptides (AMPs). The company operates through joint development and licensing agreements with industry partners, leveraging its leadership team's extensive experience in Agtech startups and advanced plant science research. Launched by the Danforth Technology Company, a subsidiary of the Donald Danforth Plant Science Center, Peptyde Bio focuses on the early-stage development of groundbreaking technologies originating from the Danforth Center's scientific endeavors. Their strategic positioning aims to address critical needs within the agricultural industry through advanced biological solutions.
How much funding has Peptyde Bio raised?
Peptyde Bio has raised a total of $1.2M across 1 funding round:
Other Financing Round
$1.2M
Other Financing Round (2022): $1.2M with participation from Danforth Technology Company, BioGenerator Ventures, QRM Capital, and St Louis Arch Angels
Key Investors in Peptyde Bio
Danforth Technology Company
The Danforth Technology Company, a subsidiary of the Donald Danforth Plant Science Center, focuses on facilitating the early-stage development of startup companies based on technologies developed by the Center's scientists.
BioGenerator Ventures
BioGenerator Ventures is an investment arm focused on supporting early-stage biotechnology and life science companies, likely providing strategic capital and operational guidance to foster innovation and growth.
St Louis Arch Angels
The St. Louis Arch Angels is a network of accredited investors dedicated to funding early-stage businesses in the St. Louis region, providing capital and mentorship to promising startups.
What's next for Peptyde Bio?
The recent major strategic investment signals a pivotal growth phase for Peptyde Bio. This financing is expected to accelerate the company's research and development initiatives, expand its collaborative partnerships, and enhance its market penetration. With a clear focus on commercializing novel AMPs, Peptyde Bio is well-positioned to capitalize on the growing demand for sustainable and effective agricultural inputs. The company's trajectory suggests a strong emphasis on scaling its operations and solidifying its market presence in the competitive Agtech landscape.
See full Peptyde Bio company page
